Assignee
IONIS PHARMACEUTICALS INC
US·261 granted patents·271 pending applications·911 citations·filing 2008–2025
Top patents by PatentIndex Score
532 records- 0198US11299736B1Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 12, 2022·3 cites·21 claims
- 0298US11236335B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2020·Granted Feb 1, 2022·6 cites·24 claims
- 0398US10493092B2Antisense compoundsIONIS PHARMACEUTICALS INC·Filed 2016·Granted Dec 3, 2019·28 cites·31 claims
- 0498US9617540B2Compounds and methods for modulating gene expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 11, 2017·26 cites·20 claims
- 0597US11851655B2Compositions and methods for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Dec 26, 2023·3 cites·33 claims
- 0697US11299737B1Compounds and methods for modulating SMN2IONIS PHARMACEUTICALS INC·Filed 2021·Granted Apr 12, 2022·3 cites·32 claims
- 0797US10844379B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2018·Granted Nov 24, 2020·8 cites·20 claims
- 0897US10294477B2Compositions and methods for modulating PKK expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 21, 2019·25 cites·21 claims
- 0997US9957504B2Compositions and methods for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 1, 2018·8 cites·56 claims
- 1097US9605263B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2016·Granted Mar 28, 2017·20 cites·20 claims
- 1197US9353372B2Compositions and their uses directed to huntingtinIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 31, 2016·16 cites·19 claims
- 1297US9321799B2Modified nucleosides, analogs thereof and oligomeric compounds prepared therefromIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 26, 2016·17 cites·24 claims
- 1396US11834660B2Compositions for modulating Ataxin 2 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·2 cites·23 claims
- 1496US11149264B2Modified compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2021·Granted Oct 19, 2021·5 cites·29 claims
- 1596US10883104B2Compositions and methods for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jan 5, 2021·5 cites·6 claims
- 1696US10683499B2Compositions and methods for modulating TTR expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Jun 16, 2020·5 cites·53 claims
- 1796US10266825B2Compositions comprising alternating 2′-modified nucleosides for use in gene modulationIONIS PHARMACEUTICALS INC·Filed 2017·Granted Apr 23, 2019·10 cites·21 claims
- 1896US10006027B2Methods for modulating Ataxin 2 expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Jun 26, 2018·21 cites·30 claims
- 1996US9932580B2Compositions and methods for modulating HBV expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 3, 2018·5 cites·42 claims
- 2096US9932581B2Compositions and methods for modulating apolipoprotein C-III expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 3, 2018·6 cites·50 claims
- 2196US9695418B2Oligomeric compounds comprising bicyclic nucleosides and uses thereofIONIS PHARMACEUTICALS INC·Filed 2013·Granted Jul 4, 2017·36 cites·17 claims
- 2296US2025346899A1Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2395US11084844B2Modified nucleosides, analogs thereof and oligomeric compounds prepared therefromIONIS PHARMACEUTICALS INC·Filed 2018·Granted Aug 10, 2021·8 cites·20 claims
- 2495US10815480B2Modulation of alpha synuclein expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Oct 27, 2020·7 cites·20 claims
- 2595US10407680B2Compounds and methods for reducing Tau expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·12 cites·31 claims
- 2695US10337007B2Oligomeric compounds comprising bicyclic nucleotides and uses thereofIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jul 2, 2019·6 cites·9 claims
- 2795US10087210B2Modified nucleosides, analogs thereof and oligomeric compounds prepared therefromIONIS PHARMACEUTICALS INC·Filed 2016·Granted Oct 2, 2018·39 cites·9 claims
- 2895US9914922B2Oligomeric compounds comprising bicyclic nucleotides and uses thereofIONIS PHARMACEUTICALS INC·Filed 2013·Granted Mar 13, 2018·14 cites·12 claims
- 2995US9714421B2Compositions and methodsIONIS PHARMACEUTICALS INC·Filed 2014·Granted Jul 25, 2017·5 cites·17 claims
- 3095US9567587B2Antisense modulation of GCCR expressionIONIS PHARMACEUTICALS INC·Filed 2014·Granted Feb 14, 2017·30 cites·24 claims
- 3195US9399774B2Modulation of transthyretin expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Jul 26, 2016·13 cites·40 claims
- 3294US12509684B2Compositions and methods for modulating apolipoprotein C-III expressionIONIS PHARMACEUTICALS INC·Filed 2024·Granted Dec 30, 2025·0 cites·20 claims
- 3394US11732261B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2020·Granted Aug 22, 2023·2 cites·20 claims
- 3494US11613752B2Compositions and methods for modulating PKK expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Mar 28, 2023·2 cites·24 claims
- 3594US10954519B2Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·5 cites·24 claims
- 3694US10570169B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2015·Granted Feb 25, 2020·11 cites·18 claims
- 3794US10538763B2Compounds and methods for modulation of DUX4IONIS PHARMACEUTICALS INC·Filed 2016·Granted Jan 21, 2020·21 cites·17 claims
- 3894US10517953B2Modulators of PCSK9 expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·5 cites·10 claims
- 3994US10344275B2Linkage modified oligomeric compoundsIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jul 9, 2019·8 cites·21 claims
- 4094US10138482B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Nov 27, 2018·11 cites·20 claims
- 4194US9957292B2Compositions and methods for modulating angiopoietin-like 3 expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 1, 2018·11 cites·81 claims
- 4294US9943604B2Targeted therapeutic nucleosides and their useIONIS PHARMACEUTICALS INC·Filed 2014·Granted Apr 17, 2018·9 cites·16 claims
- 4394US9738895B2Oligomeric compounds and methodsIONIS PHARMACEUTICALS INC·Filed 2015·Granted Aug 22, 2017·10 cites·21 claims
- 4494US9340784B2Methods and compositions for modulating alpha-1-antitrypsin expressionIONIS PHARMACEUTICALS INC·Filed 2013·Granted May 17, 2016·11 cites·14 claims
- 4593US12291709B2Compositions and methods for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2023·Granted May 6, 2025·0 cites·16 claims
- 4693US11713462B2Modulation of GYS1 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Aug 1, 2023·2 cites·17 claims
- 4793US11111494B2Compositions for modulating Ataxin 2 expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Sep 7, 2021·4 cites·27 claims
- 4893US10837016B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Nov 17, 2020·2 cites·16 claims
- 4993US10815483B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Oct 27, 2020·4 cites·20 claims
- 5093US10260069B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2014·Granted Apr 16, 2019·10 cites·12 claims
Showing the top 50 of 532 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →